Art. -Nr.: HY-173572

SKLB-11A

Kundenbewertung

Based on 1 Customer Validation

SKLB-11A is a selective, orally active and allosteric SIRT3 (sirtuin 3) agonist with a K_d value of 4.7 μM. SKLB-11A is highly selective for other members of the SIRT family. SKLB-11A activates autophagy-related signaling pathways, prevents mitochondrial dysfunction, improves cardiac function in Doxorubicin (HY-15142A)-induced cardiotoxicity and myocardial ischemia/reperfusion models.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.40%
CAS. Nr.: 433953-86-7
Formel: C₁₉H₁₅FN₄O₂
Molecular Weight:350.35

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

SKLB-11A Chemical Structure

CAS. Nr.: 433953-86-7

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- Parmacokinetics
- In Vivo
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

SIRT3

4.7 μM (Kd)

Alle Sirtuin Isoform-spezifische Produkte anzeigen :

In Vitro

SKLB-11A enhances SIRT3 deacetylation activity with an EC₅₀ of 21.95 μM^[1].
SKLB-11A (0.625-5 μM; 24 h) does not alter SIRT3 protein levels but significantly enhances SIRT3 activity in H9c2 cells^[1].
SKLB-11A binds to SIRT3 with high affinity and enhances its interaction with the p53-Ac substrate^[1].
SKLB-11A (5-20 μM; 24 h) ameliorates Doxorubicin-induced mitochondrial damage and promotes SIRT3-mediated autophagy in H9c2 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:

H9c2 cells
Concentration:

0.625 μM, 1.25 μM, 2.5 μM, 5 μM
Incubation Time:

24 h
Result:

Induced deacetylation at K122 and K68, resulting in enhanced MnSOD enzymatic activity.
Activated endogenous SIRT3 deacetylation in H9c2 cells.

Western Blot Analysis^[1]

Cell Line:

H9c2 cells
Concentration:

5 μM, 10 μM, 20 μM
Incubation Time:

24 h
Result:

Increased LC3-II expression and reduced p62 levels, indicating enhanced autophagic flux.
Increased the expression of PINK1 and Parkin, and promoted colocalization of mitochondria with Parkin and LC3-II.

Parmacokinetics

Species	Dose	Route	T_1/2	T_max	C_max	MRT_0-∞	AUC_0-∞	V_z
Rat^[1]	1 mg/kg	i.v.	0.6 h	0.08 h	254.96 μg/L	0.72 h	185.40 μg/L·h	4.66 L/kg
Rat^[1]	10 mg/kg	p.o.	5.44 h	0.25 h	67.86 μg/L	127.60 h	127.60 μg/L·h	39.99 L/kg

In Vivo

SKLB-11A (10-20 mg/kg; oral gavage; daily; for 7 days) pretreatment can repress Doxorubicin-induced cardiac dysfunction in mice^[1].
SKLB-11A (20 mg/kg; oral gavage; daily; for 7 days) treatment alleviated ischemia/reperfusion (I/R)-induced myocardial injury in mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male C57BL/6J mice (8 weeks, ~23 g)^[1]
Dosage:

10 and 20 mg/kg/day
Administration:

Oral gavage; daily; for 7 days; then injected Doxorubicin intraperitoneally for 2 weeks
Result:

Significantly restored left ventricular ejection fraction (EF) and fractional shortening (FS) in a dose-dependent manner.
Partially reversed Doxorubicin-induced weight loss and reduced serum markers of myocardial injury, including LDH, CK-MB, and BNP.
Preserved myocardial structure and alleviated pathological damage.
Demonstrated no apparent toxicity at effective doses, as evidenced by preserved organ histology in the heart, liver, spleen, lungs, and kidneys.

Animal Model:

Male C57BL/6J mice (8-12 weeks old) was induced myocardial ischemia-reperfusion (I/R) injury^[1].
Dosage:

20 mg/kg
Administration:

Oral gavage; daily; for 7 days
Result:

Restored cardiac function impaired by I/R injury.
Partially reversed I/R-induced elevations in serum myocardial injury markers, including LDH, CK-MB, and BNP.
Markedly reduced I/R-induced cardiac fibrosis.

Chemical Information

CAS. Nr. 433953-86-7
Appearance Solid
Molecular Weight 350.35
Formel C₁₉H₁₅FN₄O₂
Color Light yellow to yellow
SMILES

COC(C1=C(N)N(CC2=CC=C(F)C=C2)C3=NC4=CC=CC=C4N=C31)=O
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 7.78 mg/mL (22.21 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.8543 mL

14.2714 mL

28.5429 mL

5 mM

0.5709 mL

2.8543 mL

5.7086 mL

10 mM

0.2854 mL

1.4271 mL

2.8543 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (280 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Zhang D, et al. Unraveling Small Molecule-Mediated Sirtuin 3 Activation at a Distinct Binding Site for Cardioprotective Therapies. ACS Cent Sci. 2025 Apr 14;11(5):704-718. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.8543 mL	14.2714 mL	28.5429 mL	71.3572 mL
	5 mM	0.5709 mL	2.8543 mL	5.7086 mL	14.2714 mL
	10 mM	0.2854 mL	1.4271 mL	2.8543 mL	7.1357 mL
	15 mM	0.1903 mL	0.9514 mL	1.9029 mL	4.7571 mL
	20 mM	0.1427 mL	0.7136 mL	1.4271 mL	3.5679 mL

Keywords

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

SKLB-11A

Cell Cycle/DNA Damage Compound Library

Epigenetics Compound Library

Histone Modification Research Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Oxygen Sensing Compound Library

Anti-Cardiovascular Disease Compound Library

Orally Active Compound Library

Glutamine Metabolism Compound Library

Metabolic Enzyme Compound Library

Highly Selective Activators Library

Cell Death Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Alle Sirtuin Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

SKLB-11A

Cell Cycle/DNA Damage Compound Library

Epigenetics Compound Library

Histone Modification Research Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Oxygen Sensing Compound Library

Anti-Cardiovascular Disease Compound Library

Orally Active Compound Library

Glutamine Metabolism Compound Library

Metabolic Enzyme Compound Library

Highly Selective Activators Library

Cell Death Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Alle Sirtuin Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

SKLB-11A Related Classifications

HY-173572 Related Classifications